Skip to content

3-D Matrix is a global peptide solutions company headquartered in Tokyo, Japan, developing medical devices based on self-assembling peptide technology.

Last updated September 16, 2026

AI crawler reads

2requests

1companies
  • Anthropic2
Profile
2
Controversies
0
JSON · MD
0
First read
Nov 4, 2026
Latest read
Nov 4, 2026

From this site's server log

Overview

3-D Matrix is a global peptide solutions company headquartered in Tokyo, Japan. It began as a spinoff from MIT in 2004 and has grown into a leading global peptide solutions company with offices serving the Americas, Europe and Asia. Its mission is to develop innovative healthcare treatments that improve patient outcomes using self-assembling peptide technology. The company works with a global network of partners and distributors and serves research scientists, healthcare providers and patients around the world. Its product portfolio includes PuraStat, PuraBond and accessories for endoscopic and laparoscopic procedures.

History

In the early 1990s, MIT post-doctoral researcher Shuguang Zhang observed an unusual repeating peptide sequence while studying the peptide Zuotin, which binds to Z-DNA. This led to the discovery of self-assembling peptides, a completely new field for use in medical applications. In 2001, 3-D Matrix Inc. was established in Boston, MA, USA by Scientific Founders at MIT, to whom MIT granted an exclusive worldwide license. This facility aimed to advance the product development programme of PuraStat. In 2004, 3-D Matrix Limited was founded in Japan and received a license from 3-D Matrix Inc. In 2007, MIT and the Scientific Founders agreed the acquisition of 3-D Matrix, Inc (USA) by 3-D Matrix Limited (Japan), enabling product development to speed up and allowing 3-D Matrix to develop the business into a global company. In 2008, PuraStat was first used in clinical trials. Since its inception as a spinoff from MIT in 2004, 3-D Matrix has grown to become the leading global peptide solutions company, headquartered in Tokyo, Japan, with offices serving America, Europe and Asia.

Products and positioning

Leading global peptide solutions company

  • PuraStat

    Synthetic haemostatic gel in the form of a prefilled syringe, used for managing bleeding during procedures and proven to reduce delayed bleeds following gastrointestinal endoscopic submucosal dissection (ESD) in the colon.

  • PuraBond

    Ready to use, transparent haemostatic gel in the form of a prefilled syringe, ideal for the management of bleeding from vascular anastomoses or capillaries of the parenchyma solid organs.

  • Accessories

    Accessories specifically developed with users in mind for both endoscopic and laparoscopic procedures.

Sources5 sources

Cite this profile: Cite the canonical profile. /brand-wiki/3-d-matrix · Editorial policy · How profiles are compiled